ATOS (Atossa Therapeutics) Cash per Share: $3.68 (As of Mar. 2026)


ATOS Atossa Therapeutics Inc ATOS
26 GF Score
Price $2.45
! 2 Warning Signs
View Full Analysis

What is Atossa Therapeutics Cash per Share?

Atossa Therapeutics ATOS -1.61% 26 Cash per Share is $3.68 as of Mar. 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Atossa Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 was $3.68.

Atossa Therapeutics  (NAS:ATOS) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Atossa Therapeutics Cash per Share Related Terms

Atossa Therapeutics Cash per Share Historical Data

* Premium members only.

The historical data trend for Atossa Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atossa Therapeutics Cash per Share Chart

Atossa Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.16 13.14 10.59 8.26 4.80

Atossa Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.56 6.72 6.02 4.80 3.68
ATOS
26GF Score
Atossa Therapeutics Inc ATOS
Cash per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atossa Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Atossa Therapeutics's Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=41.299/8.61
=4.80

Atossa Therapeutics's Cash per Share for the quarter that ended in Mar. 2026 is calculated as:

Cash per Share= Cash, Cash Equivalents, Marketable Securities /Shares Outstanding (EOP)
=31.718/8.61
=3.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Cash per Share →
What does a Cash per Share of $3.68 mean?
Atossa Therapeutics (ATOS) has a Cash per Share of $3.68 as of Mar. 2026. Cash per share is the per-share value of a company's available cash. View historical data for Atossa Therapeutics and its competitors.
Is Atossa Therapeutics' Cash per Share too high?
Atossa Therapeutics' current Cash per Share is $3.68. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Cash per Share compare to QNCX and ZIVO?
Atossa Therapeutics' Cash per Share of $3.68 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash per Share for a Biotechnology company?
A good Cash per Share depends on the Biotechnology industry context. However, Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash per Share mean?
A high Cash per Share can signal that a stock is expensive relative to its fundamentals. Cash per share is the per-share value of a company's available cash. View historical data for Atossa Therapeutics and its competitors. Atossa Therapeutics's current Cash per Share is $3.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current Cash per Share of $3.68. The current Cash per Share is $3.68. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash per Share calculated?
Cash per Share is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current Cash per Share is $3.68 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Atossa Therapeutics Business Description

Other Exchanges ATOS:MexicoYAG:Germany
Address 1448 NW Market Street, Suite 500, Seattle, WA, USA, 98107
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score

Get the complete analysis for ATOS

Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.45
Price